We have reported previously on Elmiron-related eye damage, particularly that long-term use of the interstitial cystitis treatment drug Elmiron has been linked to maculopathy eye damage. In this post, we present a 2021 Elmiron medical journal article wherein it is estimated that around 20% of interstitial cystitis patients with long-term Elmiron use … [Read more...]
Testing Shows High Levels of Benzene Found In Hand Sanitizers
Valisure, a Connecticut-based online pharmacy known for testing products for quality and consistency, has found that some hand sanitizers made widely available during the early months of the coronavirus pandemic in 2020 may contain high levels of benzene. Benzene is a chemical that has been used in many different industries, but prolonged … [Read more...]
Are Heart Problems and Cancers JAK Inhibitors Drug Class Safety Issues?
Since the February 2021 FDA alert about Xeljanz-associated heart problems and possible Xeljanz-related cancers was issued, we have been watching for any related drug safety developments concerning Olumiant and Rinvoq. The reason being there has been some concern that those adverse drug events and side effects risks may apply to those other two … [Read more...]
Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma: A Multicentric Study
Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 and September 2018, epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), and c-ros oncogene 1 receptor tyrosine kinase gene (ROS1) alterations, demographic … [Read more...]
Some Information About Our Monthly Law Firm Newsletter
The Lamb Law Office Newsletter is a monthly communication from our law firm to help keep you up to date with some of the cases that we are working on for clients at the present time. In addition, we provide at least one information resource item per month, which you or someone you know might find helpful from time to time. Past … [Read more...]
New Xeljanz Warnings From FDA in 2021; Are Other JAK Inhibitors Next?
After the January 2021 release of limited data from a Xeljanz safety trial which often goes by its short name, ORAL Surveillance, some experts raised the possibility that there may consequences for other drugs in the Janus kinase (JAK) inhibitors class of drugs. Specifically, some have asked whether the FDA may extend its new Xeljanz warnings about … [Read more...]
Xeljanz 2021 FDA Warnings: Xeljanz Causing Heart Problems and Xeljanz Causing Cancer
The Xeljanz safety issues of Xeljanz causing heart problems and Xeljanz causing cancer were already "highlighted" by means of the Xeljanz Black Box Warning added back in 2019. But in February 2021 the FDA pointed out these Xeljanz side effects again in this FDA Drug Safety Communication, "Initial safety trial results find increased risk of serious … [Read more...]
Notice Violation Issued to Chemours After Failure to Properly Remove PFAS Contamination
According to a January 2021 article "N.C. regulators issue notice of violation to Chemours", the company received a violation notice regarding a newly-installed treatment system that failed to remove PFAS contamination at the Fayetteville Works site. As mentioned in previous articles, the main offender for per- and polyfluoroalkyl substances (PFAS) … [Read more...]
PFAS Levels in Cape Fear Remain Largely the Same, Despite Emission Cuts
Since our last article, "PFAS Contamination of the Cape Fear Still An Issue", the Cape Fear region continues to experience high levels of "forever chemicals" in their water supply. As mentioned in previous articles, the main offender for per- and polyfluoroalkyl substances (PFAS) contamination is the Chemours Co. Fayetteville Works Plant. … [Read more...]
FDA Approves Drug Combination for Treating Mesothelioma
[On October 02, 2020], the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic … [Read more...]